Xbrane Biopharma AB (OSTO:XBRANE)

kr 0.2295 0.0391 (20.54%) Market Cap: 351.02 Mil Enterprise Value: 517.09 Mil PE Ratio: 0 PB Ratio: 0.29 GF Score: 40/100

Q4 2023 Xbrane Biopharma AB Earnings Call Transcript
Feb 26, 2024

kr0.7 (-4.89%)

Earnings
Q4 2022 Xbrane Biopharma AB Earnings Call Transcript
Feb 17, 2023

kr10.28 (-4.12%)

Earnings
Xbrane Biopharma AB at Redeye investor forum online 2022 Transcript
Aug 31, 2022
Q1 2022 Xbrane Biopharma AB Earnings Call Transcript
May 05, 2022

kr9.82 (-1.59%)

Earnings
Q4 2021 Xbrane Biopharma AB Earnings Call Transcript
Feb 24, 2022

kr9.94 (-1.35%)

Earnings
Xbrane Biopharma press conference two new biosimilar candidates Transcript
Dec 14, 2021
Xbrane Biopharma at redeye investor forum Malmo 2021 Transcript
Dec 09, 2021
Xbrane Biopharma at Redeye life science day 2021 Transcript
Nov 16, 2021
Q2 2021 Xbrane Biopharma AB Earnings Call Transcript
Aug 13, 2021

kr17.03 (+2.88%)

Earnings

Xbrane Biopharma press conference two new biosimilar candidates Transcript

Dec 14, 2021 / NTS GMT

Release Date Price: kr12.83 (+15.39%)

Transcript

Martin Ãmark

Xbrane Biopharma AB - CEO

Hello, everybody, and welcome to this webcast. It's with the reason of us introducing two new biosimilar candidates to our portfolio, and the initial development of these two products. My name is Martin, I'm the CEO of Xbrane Biopharma, and I have with me, Siavash, our COO and the Head of our biosimilar program. So we want to spend some time now to discuss our new portfolio and do the presentation of maybe 15, 20 minutes or so. And then we'll have a session of Q&A.

Okay. Yes, I am starting with a recap from our Capital Markets Day, which we held in May this year. (technical difficulty) quite some time to talk about the (technical difficulty) similar market and what we regard to attractiveness in the market. And above all, the strong growth, which is expected in this market coming years on the back of multiple biological drugs and their patent protection and being opened up (technical difficulty) similars. (technical difficulty) some -- one of the fastest-growing segments actually, in the pharmaceutical market. We believe it's a very good opportunity for us

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.